Most cancer genome studies have focused on mutations in the tumor itself and how such gene variants allow a tumor to grow unchecked. A study led by researchers at Washington University School of Medicine in St. Louis takes a deep dive into inherited cancer mutations measured in a healthy blood sample and reports how those mutations might take a toll on the body’s cells starting at birth, perhaps predisposing a person to develop cancers at various stages of life.
Nov. 6, 2023, was a bad day for Tom Curran, a charming scientist with a lilting Scottish brogue and the lifelong dream of curing childhood cancers.
Ira Mellman was named president of research at the Parker Institute for Cancer Immunotherapy.
Cancer Research UK and partners on March 31 committed £5.5 million in funding to form a research team tasked with making personalized medicine a reality for people with colorectal cancer. The initiative is designed to unite research expertise and solve unanswered questions about the disease.
University Hospitals Cleveland Medical Center has announced a collaboration with global healthcare AI company Qure.ai to deploy chest X-ray AI supporting earlier identification of lung cancers.
The March 15 continuing resolution has gutted the Department of Defense Congressionally Directed Medical Research Program. The program’s funding was cut by 57%, compared to Fiscal Year 2024 levels—from $1.5 billion to $650 million.
Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
Jeffrey E. Lee was appointed chief medical executive at The University of Texas MD Anderson Cancer Center, effective April 1.
Tracy Smith has joined Ashish Deshmukh as a co-leader of the Cancer Prevention and Control Research Program at MUSC Hollings Cancer Center.
NCI-designated cancer centers and academic medical institutions (AMCs) are facing unprecedented threats that jeopardize their ability to conduct groundbreaking research, deliver cutting-edge care, and sustain clinical trials essential to patient treatment.
